Nagoya, Japan

Kiyotaka Hirooka


Average Co-Inventor Count = 6.3

ph-index = 1

Forward Citations = 9(Granted Patents)


Location History:

  • Aichi, JP (1995)
  • Nagoya, JP (1990 - 1996)

Company Filing History:


Years Active: 1990-1996

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Kiyotaka Hirooka: Innovator in Pharmaceutical Compounds

Introduction

Kiyotaka Hirooka is a notable inventor based in Nagoya, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating neurodegenerative diseases. With a total of 3 patents to his name, Hirooka's work is paving the way for advancements in medical treatments.

Latest Patents

Hirooka's latest patents include innovative compounds that target muscarinic receptors in the brain. One of his notable inventions is a compound designed to prevent and cure senile dementias, specifically Alzheimer's disease. This compound is characterized by a specific formula where various groups can be substituted to enhance its efficacy. Another patent focuses on nootropic agents, which are aromatic amino-substituted compounds that can potentially improve cognitive function. These compounds represent a significant step forward in the search for effective treatments for cognitive decline.

Career Highlights

Throughout his career, Kiyotaka Hirooka has been associated with Sanwa Kagaku Kenkyusho Co., Ltd., where he has been instrumental in research and development. His work has not only contributed to the scientific community but has also had a profound impact on the pharmaceutical industry.

Collaborations

Hirooka has collaborated with esteemed colleagues such as Masayasu Kurono and Tsunemasa Suzuki. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Kiyotaka Hirooka's contributions to the field of pharmaceuticals are noteworthy and demonstrate his commitment to advancing medical science. His innovative compounds hold promise for the treatment of Alzheimer's disease and other cognitive disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…